Musculoskeletal Oncology Service, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Int Orthop. 2019 Jul;43(7):1741-1747. doi: 10.1007/s00264-019-04332-y. Epub 2019 Apr 22.
Few studies have described the characteristics and prognostic factors of elderly patients with osteosarcoma. We retrospectively investigated clinico-pathological features and prognostic factors in osteosarcoma patients > 40 years old.
Patients with high-grade osteosarcoma > 40 years old who were treated at our institutions from 2000 to 2016 were recruited for this study. Information on patient, tumour, and treatment-related factors was collected and statistically analyzed. The median follow-up was 26.5 months (range, 5-139 months) for all patients.
Fifty patients (30 males and 20 females) were included. The median age at diagnosis was 59.5 years (range, 41-81 years). The primary lesions were found in the limbs in 32 patients, trunk in 12, and craniofacial bones in six. Primary and secondary osteosarcoma occurred in 41 and 9 patients, respectively. Eight patients exhibited initial distant metastasis. Definitive surgery and chemotherapy were performed in 39 patients each. The rate of good responders after neoadjuvant chemotherapy was 38%. The five year overall survival (OS) rates for all patients and those without distant metastasis at diagnosis were 44.5% and 51.1%, respectively. Multivariate analysis showed that definitive surgery was the only significant prognostic factor in non-metastatic patients. The five year OS and disease-free survival (DFS) rates for non-metastatic patients who received definitive surgery were 64.3% and 60%, respectively. Among these patients, neoadjuvant and/or adjuvant chemotherapy significantly improved both OS and DFS.
Complete surgical resection and intensive chemotherapy should be performed for osteosarcoma patients > 40 years old despite distinct clinicopathological characteristics from those of younger patients.
鲜有研究描述老年骨肉瘤患者的特征和预后因素。我们回顾性调查了我院机构治疗的年龄>40 岁的骨肉瘤患者的临床病理特征和预后因素。
本研究纳入了 2000 年至 2016 年在我院治疗的年龄>40 岁的高级别骨肉瘤患者。收集了患者、肿瘤和治疗相关因素的信息,并进行了统计学分析。所有患者的中位随访时间为 26.5 个月(范围为 5-139 个月)。
共纳入 50 例患者(30 名男性和 20 名女性)。诊断时的中位年龄为 59.5 岁(范围为 41-81 岁)。原发性病变位于 32 例患者的四肢,12 例患者的躯干,6 例患者的颅面骨。41 例为原发性骨肉瘤,9 例为继发性骨肉瘤。8 例患者初始即发生远处转移。39 例患者接受了确定性手术和化疗。新辅助化疗后的完全缓解率为 38%。所有患者和诊断时无远处转移患者的 5 年总生存率(OS)分别为 44.5%和 51.1%。多因素分析显示,对于无远处转移的患者,确定性手术是唯一的显著预后因素。接受确定性手术的无远处转移患者的 5 年 OS 和无病生存率(DFS)分别为 64.3%和 60%。在这些患者中,新辅助和/或辅助化疗显著改善了 OS 和 DFS。
尽管年龄>40 岁的骨肉瘤患者具有明显的临床病理特征,但仍应进行完全的手术切除和强化化疗。